Immune mechanisms are fundamental to the pathogenesis of many conditions which lead to severe visual impairment. For example, chronic uveitis is a significant and probably underestimated cause therapy. In one case this was achieved with two short courses of a pan-lymphocyte mAb, Campath-1H (C1H), and in the other combination therapy with C1H and an anti-CD4 mAb was required.'0 Importantly, in each situation successful treatment evolved using a iterative approach. Two further reports demonstrate the potential power of immunotherapy when applied to eye diseases. In the first, C 1H therapy controlled aggressive retinal vasculitis which had proved refractory to all prior treatments." In the second, C 1H facilitated successful corneal transplantation in a patient with a prior history of recurrent graft rejection refractory to conventional immunosuppression."
In all of the five cases referenced above, it was possible to wean conventional therapy to zero or very low levels following immunotherapy. While lymphotoxic mAbs such as C 1H have resulted in long term peripheral blood lymphopenia (although no associated immunosuppression has been demonstrated), it is now apparent that equivalent effects are attainable with non-depleting reagents."3 Even if these were immunosuppressive during the brief course (there is scant evidence to suggest this), the therapeutic index is high for any treatment which obviates the need for long term immunosuppressive drugs, and this should be a major stimulus for further research. At the basic level, we need to understand more about how the immunomodulatory agents operate. '4 In the clinic, not only is it important to institute well designed therapeutic studies but we must also try to understand more about our successes and failures. For example, vasculitis and eye disease may be particularly good targets for immunotherapy. In the former the vascular endothelium may provide a more accessible target for biological reagents than, for example, the synovium of an arthritic joint. Similarly, the unique immunological environment within the eye may facilitate the re-establishment of regulatory immune circuits following therapy of ocular disease.
Our understanding of immune physiology and pathology is increasing exponentially with the promise of yet more novel interventions. The critical factor in immunotherapeutic research is to follow the rules that govern animal research; a logical, repeatable approach based upon knowledge of appropriate immunopathology. In the future we need to adhere to these principals in ophthalmology, and if we do, cures for autoimmune diseases may well follow. 
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